Company / R&D per Share
Insulet Corporation R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.29
FY2025
5-year range
$2.43 / $4.29
FY2021-FY2025
Trend
+36.5%
vs FY2024
Sector context
#11 of 103
Health Care
What the data says
Insulet Corporation's r&d per share of $4.29 is higher than 89% of companies in the Health Care sector (FY2025). R&D per Share has increased for 9 consecutive years, from $0.98 in FY2016 to $4.29 in FY2025.
Based on SEC 10-K filings.
4.29 in FY2025 with a 5-year CAGR of +12.9%. Top quartile in the Health Care sector.
Improved from $2.95 to $4.29 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +18.1%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 103This company $4.29 Sector average $2.13
▼
+101.1% above sector average
Key checks
Key Insights
- Insulet Corporation's r&d per share has grown for 9 consecutive years.
- In FY2025, r&d per share increased 36.5% year-over-year.
- Ranks #11 out of 103 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.29 | +36.5% |
| FY2024 | $3.14 | +6.5% |
| FY2023 | $2.95 | +13.2% |
| FY2022 | $2.60 | +7.4% |
| FY2021 | $2.43 | +3.6% |
| FY2020 | $2.34 | +4.8% |
| FY2019 | $2.24 | +37.5% |
| FY2018 | $1.63 | +23.4% |
| FY2017 | $1.32 | +34.7% |
| FY2016 | $0.98 | +27.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026